<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356356</url>
  </required_header>
  <id_info>
    <org_study_id>20021640</org_study_id>
    <secondary_id>016.0040</secondary_id>
    <nct_id>NCT00356356</nct_id>
  </id_info>
  <brief_title>16.0040 Ankylosing Spondylitis Study</brief_title>
  <official_title>Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis Who Participated in Protocol 16.0037</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate extended safety and efficacy of etanercept in
      adults with Ankylosing Spondylitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, open-label extension study will evaluate the safety and clinical benefit of
      etanercept in the treatment of Ankylosing Spondylitis in subjects previously enrolled in
      Protocol 16.0037.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response (using ASAS criteria) of at least 20% and absolute improvement of at least 10 units on a 0-100 scale in at least 3 of the 4 domains</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of deterioration (using ASAS criteria) of at least 20% and absolute improvement of at least 10 units on a 0-100 scale in the potential remaining ASAS domain</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DXA and MRI scans (at selected sites)</measure>
    <time_frame>Up to 144 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>X-rays of cervical spine and lumbosacral spine</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and grade of toxicities</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS Response Criteria at weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, and the ASAS Response Criteria at 50% and 70% levels at weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 144.</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and time to partial remission as defined in Anderson, 2001: Value of &lt;20 (on a scale of 0-100) in each of the following 4 domains: VAS Patient Global Assessment, VAS Pain Score, BASFI, and BASDAI morning stiffness-related scores</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal mobility measured with Schober's test, chest expansion, and occiput to wall distance</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete joint assessment</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of inflammation using CRP</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to reduce and discontinue concomitant NSAIDs, prednisone, hydroxychloroquine, sulfasalazine, and methotrexate</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>257 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects completing 24 weeks of study drug in protocol 16.0037
        qualify to enroll into this study Other patients to meet the following criteria:

          -  Negative pregnancy test

          -  Subjects agree to use appropriate contraception throughout study

          -  Should be able to self-inject study drug or have someone who can do so

          -  Capable of understanding protocol and willing to provide written informed consent

        Exclusion Criteria:

          -  Any change in NSAID or prednisone dose within 2 weeks of baseline

          -  Any change in hydroxychloroquine, sulfasalazine, or MTX dose within 4 weeks of
             baseline

          -  Use of DMARDs other than those mentioned above, within 4 weeks of enrollment

          -  Previous receipt of ani-TNF agents, other than etanercept

          -  Receipt of any other investigational drug within 30 days of baseline

          -  Grade 3 or 4 adverse event attributed to etanercept which recurred when etanercept was
             resumed

          -  Abnormality in chemistry or hematology profiles or significant concurrent medical
             events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.enbrel.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Baraliakos X, Brandt J, Listing J, Haibel H, SÃ¶rensen H, Rudwaleit M, Sieper J, Braun J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005 Dec 15;53(6):856-63.</citation>
    <PMID>16342093</PMID>
  </results_reference>
  <results_reference>
    <citation>Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol. 2008 Apr;35(4):662-7. Epub 2008 Feb 15.</citation>
    <PMID>18278836</PMID>
  </results_reference>
  <results_reference>
    <citation>Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis. 2005 Nov;64(11):1557-62. Epub 2005 Apr 20.</citation>
    <PMID>15843448</PMID>
  </results_reference>
  <results_reference>
    <citation>Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008 Mar;67(3):346-52. Epub 2007 Oct 29.</citation>
    <PMID>17967833</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

